Impacts of diabetes mellitus on COVID-19: a literature review
Keywords:
Pandemic, COVID-19, SARS-CoV-2, Diabetes Complication, Respiratory Distress SyndromeAbstract
Introduction:
Since the beginning of the pandemic, the correlation between diabetes mellitus and the worsening of COVID-19 cases has been evaluated, since patients with diabetes mellitus infected with SARS-CoV-2 have high hospitalization rate, severe pneumonia and higher mortality. Objectives: The study sought to understand and verify the correlation of diabetes mellitus with the aggravating outcomes of COVID-19. Methods: A narrative literature review was carried out through exploratory and selective reading of articles and, finally, the recording of relevant information. The PUBMED and Google Scholar databases were used as research source, between 2000 and 2022, with the keywords: diabetes mellitus, COVID-19, COVID-19 pandemic, SARS-CoV-2 infection, SARS-CoV-2, COVID-19 viral infection, middle east respiratory syndrome coronavirus, human SRDA. Results and discussion: The articles showed that the association between diabetes mellitus and COVID-19 leads to a twofold increased risk in both mortality and severity of COVID-19. In addition, in diabetes mellitus there is a development in complications such as: endothelial and alveolar dysfunction, hypercoagulation, as well as a dysregulated immune response that contribute to serious outcomes. Conclusion: Diabetes mellitus contributes to a poor prognosis and aggravating outcomes of COVID-19 cases, however studies are needed to elucidate the mechanisms associated with these diseases.
Downloads
References
Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A. COVID-19: virology, biology and novel laboratory diagnosis. J Gene Med. 2021;23(2):1-11.
Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41(12):1100-15.
Ahirwar R, Gandhi S, Komal K, Dhaniya G, Tripathi PP, Shingatgeri VM, Kumar, K, Shama, JG, Kumar, S. Biochemical composition, transmission and diagnosis of SARS-CoV-2. Biosci Rep. 2021;41(8):1-18.
Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J. 2021;23(1).
Cheung KS, Hung IF, Chan PP, Lung KC, Tso E, Liu R et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology. 2020;159:81-95.
Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M et al. COVID-19: transmission, current treatment, and future therapeutic strategies. Mol Pharm. 2021;18(3):754- 71.
Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M. COVID-19 y diabetes mellitus: una relación bidireccional. Clin e Investig en Arterioscler. 2021;33(3):151-7.
Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13:1833-9.
Harreiter J, Roden M. Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2019). Wien Klin Wochenschr. 2019;131:6-15.
Kumar A, Arora A, Sharma P, Anil S. Is diabetes mellitus associated with mortality and severity of COVID- 19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2020;14:535-45.
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36 (7):1-9.
Landstra CP, de Koning EJ. COVID-19 and diabetes: understanding the interrelationship and risks for a severe course. Front Endocrinol (Lausanne). 2021;12:1-18.
Fleury MK. A COVID-19 e o laboratório de hematologia: uma revisão da literatura recente. Rev Bras Análises Clínicas. 2020;52(2):131-7.
Ciaccio M, Agnello L. Biochemical biomarkers alterations in coronavirus disease 2019 (COVID-19). Diagnosis. 2020;7(4):365-72.
Anghebem MI, Rego FG, Picheth G. COVID-19 e diabetes: a relação entre duas pandemias distintas. Rev Bras Análises Clínicas. 2020;52(2):28-33.
Khan M, Syed FA, Hamad ZA, Muhammad NT, Saif S, Khan ST. Epidemiology and progress so far. Molecules. 2021;26 (1):1-25.
Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection. 2021;49(2):199-213.
Huang X, Dong W, Milewska A, Golda A, Qi Y, Zhu QK et al. Human Coronavirus HKU1 spike protein uses o-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme. J Virol. 2015;89(14):7202- 13.
Hofmann H, Pöhlmann S. Cellular entry of the SARS coronavirus. Trends Microbiol. 2004;12(10):466-72.
Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: the status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2020;170:1-25.
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19 Alessandro. Cell. 2021;184:861-80.
Grudzien M, Rapak A. Effect of natural compounds on NK cell activation. J Immunol Res. 2018.
Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H et al. Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2020;93(4):1-12.
Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1-9.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9.
Mudatsir M, Fajar JK, Wulandari L, Soegiarto G, Ilmawan M, Purnamasari Y et al. Predictors of COVID-19 severity: a systematic review and meta-analysis. F1000b Research. 2021;9:1-26.
South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Hear Circ. 2020.
Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449-58.
Rachdaoui N. Insulin: the friend and the foe in the development of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(5):1-21.
Schmidt AM. Highlighting diabetes: the epidemic continues. Physiol Behav. 2016;176(1):139-48.
Kumar V, Abbas AK, Aster JC. Robbins patologia básica. 10a. GEN; 2018. 952 p.
Erener S. Diabetes, infection risk and COVID-19. Molec Metabolism. 2020;39:1010-44.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.
Rao S, Lau A, So HC. Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: A mendelian randomization analysis highlights tentative relevance of diabetes-related traits. Diabetes Care. 2020;43(7):1416-26.
Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Agoramoorthy G, Lee SS. Diabetes and COVID-19: a major challenge in pandemic period? Eur Rev Med Pharmacol Sci. 2020;24(21):11409-20.
Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057-69.
Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2004; 286 p.
Sobel BE, Schneider DJ. Platelet function, coagulopathy and impaired fibrinolysis in diabetes. Cardiol Clin. 2004;22:511-26.
Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-57.
Anandhalakshmi S, Manikandan S, Ganeshkumar P, Ramachandran C. Alveolar gas exchange and pulmonary functions in patients with type II diabetes mellitus. J Clin Diagnostic Res. 2013;7(9):1874-7.
EBC. Empresa brasileira de comunicação. Mortalidade pela COVID-19 é 57% maior em pacientes com diabetes. 2021. Disponível em: https://radios.ebc.com.br/tarde-nacional/2021/04/mortalidade-por-covid-19-e-57-maior-em-pacientes-com-diabetes. Acesso em: 6. fev. 2022.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult in patients with COVID-19. In: Wuhan, China: a retrospective cohort study. J Med Study Res. 2020;395(1):1054-62.
Varikasuvu SR, Dutt N, Thangappazham B, Varshney S. Diabetes and COVID-19: a pooled analysis related to disease severity and mortality. Prim Care Diabetes. 2020;15:24-7.
Wang W, Lu J, Gu W, Zhang Y, Liu J, Ning G. Care for diabetes with COVID-19: Advice from China. J Diabetes. 2020;12(5):417-9.
Bornstein SR, Gallwitz B, Kellerer M, Ludwig B, Müller- Wieland D, Neu A et al. Practical recommendations of the German Diabetes Society for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrino. 2020;8(1):546-50.
Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia e a systematic review, meta-analysis, and meta-regression. Ann Oncol. 2020;19-22.
Aggarwal G, Lippi G, Lavie CJ, Henry BM, Sanchis- Gomar F. Diabetes mellitus association with coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. J Diabetes. 2020;12(11):851-5.
De Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, De Souza FD, Rodacki M et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020;12:1-12.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020;180(7):934-43.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors and reviewers must disclose any financial, professional, or personal conflicts of interest that could influence the results or interpretations of the work. This information will be treated confidentially and disclosed only as necessary to ensure transparency and impartiality in the publication process.
Copyright
RBPS adheres to the CC-BY-NC 4.0 license, meaning authors retain copyright of their work submitted to the journal.
- Originality Declaration: Authors must declare that their submission is original, has not been previously published, and is not under review elsewhere.
- Publication Rights: Upon submission, authors grant RBPS the exclusive right of first publication, subject to peer review.
- Additional Agreements: Authors may enter into non-exclusive agreements for the distribution of the RBPS-published version (e.g., in institutional repositories or as book chapters), provided the original authorship and publication by RBPS are acknowledged.
Authors are encouraged to share their work online (e.g., institutional repositories or personal websites) after initial publication in RBPS, with appropriate citation of authorship and original publication.
Under the CC-BY-NC 4.0 license, readers have the rights to:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material.
These rights cannot be revoked, provided the following terms are met:
- Attribution: Proper credit must be given, a link to the license provided, and any changes clearly indicated.
- Non-Commercial: The material cannot be used for commercial purposes.
- No Additional Restrictions: No legal or technological measures may be applied to restrict others from doing anything the license permits.
